宫颈癌的相关免疫治疗及进展

Related Immunotherapy and Progress of Cervical Cancer

宫颈癌是最常见的妇科恶性肿瘤,严重威胁女性健康。高危型人乳头瘤病毒(human papillomavirus,HPV)持续感染是宫颈癌的主要危险因素。近年来,HPV疫苗在宫颈癌预防方面取得了良好的效果,免疫治疗也成为了宫颈癌治疗的新模式,尤其对于手术、放化疗效果不佳和术后转移及晚期复发的患者,免疫治疗尤为重要。免疫治疗的策略主要包括免疫检查点抑制剂、疫苗治疗、树突状细胞免疫疗法和过继细胞免疫疗法。目前,相关的免疫疗法在宫颈癌及其癌前病变治疗的研究中均取得了不错的疗效。综述宫颈癌中的免疫治疗进展,并对今后的研究方向做出展望,从而为宫颈癌的临床治疗和基础研究提供依据。

Cervical cancer is the most common gynecological malignant tumor,which is a serious threat to women′s health.High-risk human papillomavirus(HPV)persistent infection is the main risk factor of the cervical cancer.In recent years,HPV vaccine has achieved favorable results in the prevention of cervical cancer.Immunotherapy has also become a new pattern of treatment of cervical cancer,especially for patients with poor effect of surgery,radiotherapy and chemotherapy,postoperative metastasis and late recurrence.The strategies of immunotherapy mainly include immune checkpoint inhibitors,vaccine therapy,dendritic cell immunotherapy and adoptive cellular immunotherapy.At present,the related immunotherapy has achieved good results in the treatment of cervical cancer and its precancerous lesions.This article will describe the progress of immunotherapy in cervical cancer,and look forward to the future research direction,so as to provide a basis for clinical treatment and fundamental research of cervical cancer.